Hospital Quironsalud Zaragoza — Clinical Trial Site

15 Registered trials

4 Currently recruiting

Organisation

Hospital Quironsalud Zaragoza

Location

Zaragoza, Spain

Identifier

ORG-100041386

Address

Paseo Renovales S/n, 50006, Spain

Departments

#7013: Oncologia Medica
ES30013: Oncologia Medica
Haematology
Hematology
Hospital Quironsalud Zaragoza( #1)
n/a
Oncology
Quironsalud Floresta.

Clinical trials at this site (15)

Search interface

A PHASE 2 STUDY TO RESEARCH THE SAFETY AND EFFICACY OF TRASTUZUMAB DERUXTECAN VERSUS CDK4/6I PLUS ENDOCRINE THERAPY IN ADVANCED BREAST CANCE… Recruiting

2024-512360-55-00 Unresectable locally recurrent or metastatic hormone re 4 2025-06-30
A Prospective, Open-Label, Randomized, Interventional Study to Evaluate the Efficacy and Tolerability of Sucrosomial® Iron vs Ferric Maltol … Recruiting

2025-522004-24-00 iron deficient 11 2025-12-11
Adding Navtemadlin to Ruxolitinib for Patients with Myelofibrosis Recruiting

2023-504724-25-00 Primary Myelofibrosis 5 2024-10-16
A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants with Chronic Mye… Recruiting

2023-507677-18-00 Chronic Myeloid Leukemia 9 2024-05-17
A Multicenter, Long-term, Follow-up Study to Investigate the Safety and Durability of Response Following Dosing of an Adeno-associated Viral… Ended

2024-511172-33-00 Gaucher Disease Type 1 9 2024-05-10
A PHASE 1/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SELINEXOR, A SELECTIVE INHIBITOR OF NUCLEAR EXPORT, IN COMBINATION WITH RUXOLITINIB… Ended

2023-506139-13-00 Treatment naïve patients with MF 5 2024-01-04
A Phase 3 Study of Rusfertide (PTG-300) in Patients with Polycythemia Vera Ended

2023-509750-58-00 Polycythemia Vera 5 2022-09-21
A study to evaluate KER-050 as a monotherapy or in combination with Ruxolitinib in Myelofibrosis. Ended

2023-507468-38-00 Myelofibrosis 4 2022-04-22
A study comparing current available therapies with imetelstat for the treatment of intermediate-2 or high-risk MF who are not responding to … Ended

2023-509120-17-00 Myelofibrosis 5 2021-04-12
A Study of TL-895 in Myelofibrosis, Indolent Systemic Mastocytosis, Monoclonal Mast Cell Activation Syndrome, or Non-Monoclonal Mast Cell Ac… Ended

2024-514467-26-00 Indolent Systemic Mastocytosis 4 2021-04-07
A study to determine the long-term safety and tolerability of oral lucerastat in adult subjects with Fabry disease Ended

2024-513884-20-00 Fabry disease 5 2019-03-13
KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treat… Ended

2024-513912-89-00 Primary Or Secondary (Post-PV MF or Post-ET-MF) Myelofi 10 2018-12-13
A Phase 3 Study of Zanubrutinib (BGB-3111) Compared with Bendamustine plus Rituximab in Patients with Previously Untreated Chronic Lymphocyt… Ended

2023-509976-40-00 Untreated Chronic Lymphocytic Leukemia or Small Lymphoc 5 2018-05-28
A dose finding study of LY3884961 in patients with Gaucher disease Halted

2022-500281-10-02 Type 1 Gaucher Disease (Peripheral/Non-neuronopathic Ma 9 2026-02-06
Safety and Efficacy of Eliglustat With or Without Imiglucerase in Pediatric Patients With Gaucher Disease (GD) Type 1 and Type 3 Ended

2024-510751-34-00 Gaucher's disease type I; Gaucher's disease type III 5 2019-03-26